Brain Connectivity-Targeted tACS Trial in Early AD

V2, Crosslink

🧫

Brain Connectivity-Targeted tACS Trial in Early AD

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-brain-co

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Brain Connectivity-Targeted tACS Trial in Early AD ## Background and Rationale Alzheimer's disease (AD) pathogenesis involves early network dysfunction preceding overt neurodegeneration, with resting-state fMRI revealing paradoxical hyperconnectivity in default mode network (DMN) regions during mild cognitive impairment (MCI) stages. This hyperconnectivity may facilitate trans-synaptic spread of pathological tau protein through anatomically connected brain regions, accelerating disease progres

METHODOLOGY NOTES

Phase 1 (Screening, Days -14 to 0): Screen participants meeting MCI criteria with evidence of AD pathology via CSF biomarkers or PET imaging. Conduct baseline assessments including resting-state fMRI (10-minute acquisition), structural MRI, comprehensive neuropsychological battery (ADAS-Cog, MoCA, episodic memory tests), and lumbar puncture for biomarkers. N=60 participants randomized 1:1 to active tACS versus sham. Phase 2 (Stimulation Protocol, Days 1-28): Deliver personalized tACS using individual fMRI connectivity maps to position electrodes over hyperconnected DMN regions. Apply 40 Hz stimulation at 2 mA peak-to-peak intensity for 20 minutes per session, 5 sessions weekly for 4 weeks. Sham group receives identical setup with imperceptible current (30 seconds ramp-up only). Monitor adverse events and tolerability daily. Phase 3 (Immediate Assessment, Days 29-35): Repeat baseline assessments including resting-state fMRI, cognitive testing, and biomarker sampling within one week post

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.902430Z'}
summary	# Brain Connectivity-Targeted tACS Trial in Early AD ## Background and Rationale Alzheimer's disease (AD) pathogenesis involves early network dysfunction preceding overt neurodegeneration, with restin
entities	{'genes': ['MCI'], 'diseases': ["Alzheimer's Disease"]}
model_system	mouse
_schema_version	1
experiment_type	clinical
primary_outcome	Validate Brain Connectivity-Targeted tACS Trial in Early AD
methodology_notes	Phase 1 (Screening, Days -14 to 0): Screen participants meeting MCI criteria with evidence of AD pathology via CSF biomarkers or PET imaging. Conduct baseline assessments including resting-state fMRI
replication_status	replicated
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.902434', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

559

Outgoing

474

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Brain Connectivity-Targeted tACS Trial in Early AD

derives from (16)

supports (5)

💬 Discussion